Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
ZTS Zoetis Inc
HMPT Home Point Capital Inc
KWR Quaker Chemical Corp
TWO Two Harbors Investment Corp
BV Brightview Holdings Inc
PBPB Potbelly Corp
RLJ RLJ Lodging Trust
LHCG LHC Group Inc
KW Kennedy-Wilson Holdings Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Closing Price
$116.08
Day's Change
0.30 (0.26%)
Bid
--
Ask
--
B/A Size
--
Day's High
116.18
Day's Low
114.16
Volume
(Average)
Volume:
5,803,752

10-day average volume:
6,301,980
5,803,752

Company Profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Valuation Ratios

Price/Earnings (TTM)
42.72x
Price/Sales (TTM)
4.46x
Price/Book (MRQ)
15.63x
Price/Cash Flow (TTM)
18.42x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

April 2021
Current Month
18.7M
Previous Month
15.8M
Percent of Float
1.06%
Days to Cover
2.9376 Days

Share Information

ABBV is in a share class of common stock
Float
1.8B
Shares Outstanding
1.8B
Institutions Holding Shares
3,192
67.36%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Richard A. GonzalezChmn.
  • Michael E. SeverinoPres.
  • Laura J. Schumacher
  • Robert A. MichaelCFO
  • Timothy J. Richmond

Address

Insider Trading

During the most recent quarter, 714K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.